Cost-effectiveness of artesunate for the treatment of severe malaria

Tropical Medicine and International Health

Volumn 14, Issue 3, 2009, Pages 332-337

  Lubell, Y ^a   Yeung, S ^a   Dondorp, A M ^b   Day, N P ^b   Nosten, F ^c   Tjitra, E ^d   Abul Faiz, Md ^e   Bin Yunus, E ^f   Anstey, N M ^b   Mishra, S K ^g   Mohanty, S ^g   White, N J ^b   Mills, A J ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^c SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^d NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT   (Indonesia)

^e DHAKA MEDICAL COLLEGE   (Bangladesh)

^f CHITTAGONG MEDICAL COLLEGE   (Bangladesh)

^g ISPAT GENERAL HOSPITAL   (India)

Author keywords

Artemisinin; Artesunate; Cost; Economic; Malaria; Quinine

Indexed keywords

ARTESUNATE; QUININE;

COST-BENEFIT ANALYSIS; DISEASE TREATMENT; DRUG; HEALTH POLICY; MALARIA; MORTALITY; QUININE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA COLLECTION METHOD; DISEASE SEVERITY; DRUG COST; HUMAN; MALARIA; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; SOUTHEAST ASIA;

ANTIMALARIALS; ARTEMISININS; ASIA, SOUTHEASTERN; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE COSTS; HUMANS; MALARIA; QUININE; TREATMENT OUTCOME;

ASIA; EURASIA; SOUTHEAST ASIA;

ARTESUNATE;

EID: 60349111924     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2009.02227.x     Document Type: Article

References (22)

1. Agnamey P, Brasseur P, Cisse M et al. (2005) Economic evaluation of a policy change from single-agent treatment for suspected malaria to artesunate-amodiaquine for microscopically confirmed uncomplicated falciparum malaria in the Oussouye District of south-western Senegal. Tropical Medicine and International Health 10, 926 933.
2. Anstey NM, Price RN White NJ (2006) Improving the availability of artesunate for treatment of severe malaria. Medical Journal of Australia 184, 3 4.
3. Dondorp A, Nosten F, Stepniewska K, Day N White N (2005) Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366, 717 725.
4. Drummond MF, O'Brien B, Stoddart GL, Torrance GW Sculpher MJ (2005) Methods for the Economic Evaluation of Health Care Programmes, 3rd Edn. Oxford University Press, Oxford.
5. Gold MR, Siegel JE, Russell LB Weinstein MC (1996) Cost Effectiveness in Health and Medicine. Oxford University Press, New York.
6. Grieve R, Nixon R, Thompson SG Cairns J (2007) Multilevel models for estimating incremental net benefits in multinational studies. Health Economics 16, 815 826.
7. Hien TT, Day NPJ Phu NH et al. (1996) A Controlled Trial of Artemether or Quinine in Vietnamese Adults with Severe falciparum Malaria. New England Journal of Medicine 335, 76.
8. Honrado ER, Fungladda W Kamoiratanaku P et al. (1999) Cost-effectiveness analysis of artesunate and quinine + tetracycline for the treatment of uncomplicated falciparum malaria in Chanthaburi, Thailand. Bulletin of the World Health Organization 77, 235 243.
9. Jamison DT, Mosely WH, Measham AR Bobadilla JL (1993) Disease Control Priorities in Developing Countries. Oxford University Press, Oxford.
10. Jones KL, Donegan S Lalloo DG (2007) Artesunate versus quinine for treating severe malaria. Cochrane Database of Systematic Reviews, 4 : CD005967-CD005967. MSH (2007). International Drug Price Indicator Guide, http://erc.msh.org/dmpguide.
11. Mulligan J, Morel C Mills A (2005) The Cost-Effectiveness of Malaria Control Interventions. Supporting paper for Disease Control Priorities in Developing Countries. 2nd Edn 2006) Oxford University Press, Oxford, England.
12. Nixon RM Thompson SG (2004) Parametric modelling of cost data in medical studies. Statistics in Medicine 23, 1311 1231.
13. Pittler MH Ernst E (1999) Artemether for severe malaria: a meta-analysis of randomized clinical trials. Clinical Infectious Diseases 28, 597 601.
14. Sachs J (2002) Macroeconomics and Health: Investing in Health for Economic Development. WHO, Geneva.
15. Utzinger J, Tozan Y Singer BH (2001) Efficacy and cost-effectiveness of environmental management for malaria control. Tropical Medicine and International Health 6, 677 687.
16. White NJ (1983) Severe hypoglycemia and hyperinsulinemia in falciparum malaria. New England Journal of Medicine 309, 61 66.
17. WHO (2006) Guidelines for the Treatment of Malaria. WHO, Geneva.
18. WHO (2007) Global AMDP Database - SEARO. WHO, Geneva. http://www.who.int/malaria/amdp/amdp-searo.htm (accessed 27 June 2008).
19. WHO (2008a) CHOosing Interventions that are Cost-Effective: Country Specific Costs. WHO, Geneva.
20. WHO (2008b) Life Tables for WHO Member States. http://www.who.int/whosis/ database/life-tables/life-tables-process.cfm?path=whosis,life- tables&language=english (accessed on 12th November 2008).
21. Wiseman V, Kim M, Mutabingwa TK Whitty CJ (2006) Cost-effectiveness study of three antimalarial drug combinations in Tanzania. PLoS Medicine 3, e373.
22. Yeung S (2006) Antimalarial Drug Resistance and Artemisinin Combination Therapy: A Bio-Economic Model for the Elucidation of Policy. PhD thesis, LSHTM, London.